David O’Connell, director of scientific affairs at PCI Pharma Services, explores how enabling technologies are helping targeted protein degraders (TPDs) overcome their biggest challenge.
PCI Pharma Services
Overcoming targeted protein degraders biggest challenge
David O’Connell, director of scientific affairs at PCI Pharma Services, explores how enabling technologies are helping targeted protein degraders (TPDs) overcome their biggest challenge.
Published:
|
2 min read
Last updated:
Sign up to our newsletter
The week's biggest stories from this industry, direct to your inbox.